Intuitive Surgical (ISRG) has spent most of 2026 being sold. The stock is down roughly 33% year-to-date, sitting near $379 against a consensus analyst target around $500. That gap is either a value opportunity or a warning. The Q2 numbers argue for the former.
Why This Stock Now
Q2 2026 revenue came in at $2.89 billion, up 19% year-over-year. Recurring revenue grew 19% to $2.47 billion, representing about 85% of total revenue. Instruments and accessories were up 18% to $1.73 billion. Service revenue rose 21% to $472 million. The business is not shrinking; it is compounding on a massive installed base. The stock is down because of sector pressure, not operating deterioration.
The Business
Intuitive Surgical is the leading player in robotic-assisted surgery. Its da Vinci platform covers soft tissue procedures across general surgery, urology, gynecology, cardiothoracic care, and head and neck specialties. The Ion platform extends the company into minimally invasive lung biopsy. The model is designed around recurring revenue: once a hospital installs a da Vinci system, every subsequent procedure generates instrument, accessory, and service revenue. With approximately 11,710 da Vinci systems installed globally as of June 30, 2026, and more than 20 million cumulative procedures performed, the installed base is the moat.
Why Wall Street Is Paying Attention
Da Vinci 5 accounted for about 85% of U.S. system placements in Q1 2026. Its utilization rate has been described as running roughly 10% above the legacy Xi platform, reflecting the new system’s capabilities, including Force Feedback. In Q1, Intuitive placed 431 da Vinci systems total, versus 367 a year earlier. International da Vinci procedures rose 20% in Q2, with Europe and Asia both up 20%. SP procedures increased 61%. UBS upgraded ISRG to Buy on July 28. Oppenheimer upgraded to Outperform on August 12, citing a lack of meaningful U.S. competition. Citi held its Buy rating in mid-July, and Piper Sandler maintained an Overweight rating in July. Aggregated analyst tallies vary by service, but the mix remains heavily tilted toward Buy-equivalent ratings.
What’s Driving the Opportunity
The da Vinci 5 upgrade cycle is still early. The platform carries higher revenue per procedure than its predecessor, and early retention in Intuitive’s subscription-style offerings has been a meaningful signal that software-driven workflow tools can be sticky. Management maintained 2026 worldwide da Vinci procedure growth guidance at 13.5% to 15.5%. The company also received FDA 510(k) clearance in March 2026 for da Vinci Force Feedback Instruments, which broadens the platform’s capabilities. Competitors including Medtronic’s Hugo and Johnson and Johnson’s Ottava have not yet established meaningful U.S. footholds, and Intuitive is deploying da Vinci 5 precisely to lock in hospital capital budgets before those rivals scale.
What Could Go Wrong
The sector headwinds are not imaginary. Intuitive itself has said its 2026 outlook range considers the impact of changes to ACA premium subsidies and patient behavior in the U.S. China and Japan have been drags at times, with tender timing and competitive intensity weighing on growth. GLP-1 adoption is also a pressure point: Intuitive has reported declines in U.S. bariatric procedures. Even after the pullback, the valuation assumes sustained double-digit procedure growth. Any deceleration in the upgrade cycle would be punished.
The Bottom Line
A 33% year-to-date decline in a company generating $2.89 billion in quarterly revenue with an 85% recurring mix and no clear, scaled U.S. challenger in its core market is not the same thing as a broken thesis. The stock has been priced for risks that are real but partially visible. The da Vinci 5 cycle is driving faster utilization, higher recurring revenue per system, and accelerating software adoption. With a consensus target around $500 and a current price near $379, ISRG is the strongest large-cap healthcare setup available today.
